Moreover,
Spear bio launches new generation:
Spear Bio. Nevertheless, a pioneering biotechnology company Pioneer of Ultrasensible Immunoessai technology technology, announced today the commercial launch of its ultradect lance™ Immuno-Essai solution. Moreover, It offers unnecessary sensitivity, specificity, precision and scalability for a measure of robust biomarkers. Nevertheless, The initial launch includes four tests. Nevertheless, targeting the main neurology biomarkers: Tau 231 Phosphorylated (Ptau231), TAU 217 Phosphorylated (Ptau217), Fibrillar Glial (GFAP) and Neurofilament (NFL). Meanwhile, Spear Bio will collaborate with Bio-Techne to distribute Immunoes Spear Ultradetect worldwide.
Unlike traditional ultrasensible technologies. which are based on heterogeneous formats that require solid surface capture and several washing stages, SPEAR Bio owner technology is the first homogeneous immunodosage platform that reaches ultra-sensitivity without washing stages. It specifically quantifies the biomarkers of proteins at attomolar concentrations from 1 µl of diluted sample. considerably exceeding the most sensitive heterogeneous platforms on the market.
Lance spear bio launches new generation technology also takes up long -time specific challenges by eliminating the common non -specific link in heterogeneous tests. considerably reducing the false positive results. Its innovative two-factor innovative authentication mechanism guarantees that the signal only occurs when antibody pairs are co-logged on target. proteins over an extended period of time.
The unmatched sensitivity. specificity and precision provided by spear-totectect immunossesses are essential to reliably measure neurology biomarkers with low abundance, especially in peripheral blood where these are often present at trace levels due to the hemato-encephalic barrier. Ultradect’s immunosseais can be read on a wide range of QPCR systems adopted in clinical research. laboratories, with very coherent results on various QPCR instruments and formats. This allows unique robustness, scalability and ease of integration in existing laboratory workflows.
We are proud to deliver the first solution of ultra-sensitive immuno-Essai of its kind which could potentially resolve the challenges that researchers spear bio launches new generation in neurology working with blood-based biomarkers have been confronted for years.
SPAR Ultradetect will allow university and clinical researchers around the world to unlock new ideas and improve therapies and treatments for a variety of neurological conditions. “”
Feng Xuan, PHD, co-founder and CEO, Spear organic
Immunoessai Spear Ultradetect’s solution will be presented at the International Conference of the Association of Alzheimer 2025 (AAIC), from July 27 to 30 in Toronto, Canada, Stand # 1527.
Spear bio launches new generation
Further reading: The best fruit to prevent colon cancer, according to a gastroenterologist: “a reduced risk by 13%” – Our best weapon against antibiotic resistance? – Seven people per year die drowned by trying to save people – Medical devices: Approval of a joint declaration to strengthen governance and coordination of the European regulatory system – The updated care course.
